Asciminib is a prescription medication used in the treatment of chronic myeloid leukemia (CML). It is a type of targeted therapy medication that works by blocking the activity of an enzyme called BCR-ABL tyrosine kinase. This enzyme is responsible for the production of certain proteins that cause CML cells to grow and divide rapidly. By blocking the activity of this enzyme, asciminib can slow down the growth of CML cells, leading to better control of the disease.
Asciminib, sold under the brand name Scemblix, is a medication used to treat a specific type of chronic myeloid leukemia (CML) called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) [1]. Here's a detailed description of Asciminib:
Function:
- Tyrosine kinase inhibitor (TKI): Belongs to a class of drugs that target and block specific enzymes (tyrosine kinases) involved in the growth and survival of cancer cells.
- Specifically targets ABL1 kinase: In Ph+ CML, a genetic abnormality creates a fusion protein called BCR-ABL1, which drives the uncontrolled growth of leukemia cells. Asciminib specifically targets the ABL1 kinase domain within this fusion protein, thereby inhibiting its activity and hindering the growth of cancer cells.
Uses:
- Chronic Phase CML: Approved for the treatment of adult patients with Ph+ CML in chronic phase who have previously been treated with at least two other TKIs and failed to respond to those treatments.
- T315I mutation: Additionally, Asciminib is indicated for adult patients with Ph+ CML who harbor the T315I mutation. This mutation makes the cancer cells resistant to most other TKIs, making Asciminib a valuable treatment option in such cases.
Administration:
- Oral tablets: Taken by mouth, typically once or twice daily depending on the specific indication and treatment regimen.
Mechanism of action:
- Blocks ABL1 kinase activity: By binding to the ABL1 kinase domain, Asciminib prevents it from transferring phosphate groups to other proteins, a crucial step in cell signaling pathways that promote cancer cell growth and survival. This ultimately leads to starvation and death of the leukemia cells.
Advantages:
- Effective against T315I mutation: Offers a treatment option for patients with CML who have developed resistance to other TKIs due to the T315I mutation.
- Well-tolerated: Generally well-tolerated compared to other TKIs, with a lower risk of certain side effects like fluid buildup (edema).
Considerations:
- Relatively new drug: Long-term safety data is still being gathered.
- Potential side effects: Common side effects can include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea.
- Not a first-line treatment: Typically used for patients who have not responded to other treatment options.
- Requires ongoing monitoring: Regular blood tests and monitoring for side effects are crucial during treatment with Asciminib.